Treatment of Viable Parenchymal Neurocysticercosis with More Than 2 Parenchymal Cysticerci and No Elevated Intracranial Pressure
Clinical Scenario
This protocol covers patients with viable parenchymal neurocysticercosis (VPN) confirmed on imaging who have more than two viable parenchymal cysticerci and no evidence of elevated intracranial pressure. In the absence of elevated intracranial pressure, antiparasitic therapy is recommended in all such patients.
Treatment Approach (Partial Overview)
The recommended approach for this specific burden of disease involves a combination of two antiparasitic agents used together, with adjunctive corticosteroid therapy initiated before antiparasitic treatment begins. Patients who experience seizures require antiepileptic coverage as part of the regimen. The complete protocol — including specific agents, sequencing, and full duration — is available via the structured evidence-based regimen.
Treatment Goal: Radiologic resolution of the parenchymal cystic component on MRI by 6 months. Follow-up MRI is recommended at least every 6 months until cystic resolution is confirmed.
References
DOI: 10.1093/cid/cix1084
In the absence of elevated intracranial pressure, we recommend use of antiparasitic drugs in all patients with VPN (strong, moderate).
We recommend albendazole (15 mg/kg/day) combined with praziquantel (50 mg/kg/day) for 10–14 days rather than albendazole monotherapy for patients with >2 viable parenchymal cysticerci (strong, moderate).
We recommend adjunctive corticosteroid therapy begun prior to antiparasitic drugs rather than no adjunctive therapy in all patients treated with antiparasitic therapy (strong, moderate).
We recommend antiepileptic drugs in all NCC patients with seizures (strong, low).
We suggest that MRI be repeated at least every 6 months until resolution of the cystic component (strong, low).
View source ↗